| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2009;53:64.)
© 2009 American Heart Association, Inc.
Original Articles |
From the Hypertension Unit (L.F.D., L.A.B., E.M.K.) and Sleep Laboratory (G.L.-F.), Pulmonary Division, Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.
Correspondence to Luciano F. Drager, Hypertension Unit, Heart Institute (InCor), University of São Paulo Medical School, Av Dr Enéas Carvalho de Aguiar, 44, CEP 05403-904, São Paulo, Brazil. E-mail luciano.drager{at}incor.usp.br
| Abstract |
|---|
|
|
|---|
Key Words: obstructive sleep apnea atherosclerosis hypertension stroke cardiovascular disease
| Introduction |
|---|
|
|
|---|
40%, and the presence of HTN could be the result of the interaction of environmental and genetic factors.13 HTN is a well-known condition associated with atherosclerosis,14 and the coexistence of OSA and HTN may have additive effects on the risk of atherosclerosis. In the present study, we evaluated the impact of OSA and HTN alone compared with the association of both conditions on markers of early carotid atherosclerosis. To this end, we carefully selected a subgroup of participants with no history of smoking and diabetes mellitus. We hypothesized that OSA and HTN have additive effects on carotid atherosclerosis, which could contribute to increase the risk of myocardial infarction and stroke.
| Methods |
|---|
|
|
|---|
After the sleep study, we only studied subjects with no OSA or moderate-to-severe OSA apnea-hypopnea index (AHI) <5 and >15 events per hour, respectively). OSA patients were recently diagnosed and not treated. The study design allowed us to define 4 groups, as follows: (1) volunteers without OSA and HTN (controls); (2) OSA patients without HTN (OSA); (3) non-OSA patients with HTN (HTN); and (4) OSA patients with HTN (OSA+HTN). We excluded participants who regularly took medications other than antihypertensive agents. All of the patients with HTN were outpatients from the Hypertension Unit, Heart Institute (InCor), with a previous investigation for other causes of secondary HTN. HTN was previously diagnosed according to current guidelines.12 In addition, no patients had a history of the white-coat effect. Blood pressure measurements were determined on separate occasions by
3 readings of systolic and diastolic (phase V) blood pressures obtained at 5-minute intervals with a conventional mercury sphygmomanometer, after participants had been seated for
15 minutes. To classify each participant as normotensive or hypertensive, experienced physicians who were not involved in the study performed blood pressure measurements according standard measurements criteria.12 Further measurements were performed by the same researcher (L.F.D.) confirming the blood pressure levels. The cutoff point for HTN was 140/90 mm Hg.12 For ethical reasons, all of the hypertensive patients were on medications for blood pressure control. To avoid acute effects of antihypertensive treatment, patients did not take medications on the day that vascular parameters were measured, as described previously from different groups.16–18
Sleep Study
All of the participants underwent a standard overnight polysomnography (EMBLA - Flagra hf. Medical Devices), as described previously.9 Apnea was defined as complete cessation of airflow for
10 seconds, associated with oxygen desaturation of 3%. Hypopnea was defined as a significant reduction (>50%) in respiratory signals for
10 seconds associated with oxygen desaturation of 3%. The AHI was calculated as the total number of respiratory events (apneas plus hypopneas) per hour of sleep.
Vascular Parameters
All of the participants had their vascular parameters evaluated by an experienced observer (L.A.B.), blinded to the clinical condition of each participant. All of the measurements were taken between 2 PM and 4 PM, with the patient in a recumbent position while awake. We used a high-resolution echo-tracking system (Wall Track System, Neurodata), which is based on the radio-frequency signal analysis that has been described, validated, and used in previous clinical studies.19 The accuracy of the system is 30 µm for the diastolic diameter measurement and <1 µm for the pulsatile change in diameter (difference between systolic and diastolic diameters).20 All of the measurements were performed on the right common carotid arteries 1 cm below the bifurcation at the site of the distal wall, as assigned in other studies using the same methodology.19,20
Intima-Media Thickness
Carotid IMT was measured at the thickest point on the near and far walls with a specially designed computer program. A high rate of IMT reproduction has been demonstrated previously.21 Plaque was defined as a localized thickening >1.2 mm that did not uniformly involve the whole artery, and, if present, the measurements were taken
1 cm away from plaque.9
Carotid Diameter
The high-resolution echo-tracking system determined the transcutaneous assessment of arterial wall displacement during the cardiac cycle and, hence, of the time-dependent changes in arterial diameter relative to initial diameter at the start of the cardiac cycle. The radio-frequency signal of 4 to 8 cardiac cycles was recorded, digitized, and temporarily stored in a large memory bank. We determined the signals corresponding with the proximal and the distal walls and, therefore, measured the posterior wall thickness and the internal diameter by positioning markers in the respective posterior and anterior wall signals. The system computed the successive values of internal end-diastolic diameter and stroke change in diameter and digitized the displacement waveform.
Carotid Distensibility
Carotid distensibility was calculated from the mean of 2 consecutive measurements in parallel with measurements from beat-to-beat blood pressure monitoring (Portapres, TNO Biomedical Instrumentation), which has been shown to accurately estimate intra-arterial blood pressure.22 Continuous blood pressure measurements were performed in a supine position. The mean values of arterial diastolic diameter (d), distension (
d; defined as the difference between systolic and diastolic diameter during heart cycle), IMT, and carotid pulse pressure (
P; estimated as the difference between systolic and diastolic arterial pressure obtained by noninvasive beat-to-beat concomitant measurement by Portapres) were used for analysis. Distensibility was calculated by using the following equations: distensibility (D)=(2
d.d+
d2)/(
P.d2).19 Results are expressed as kPa–1·10–3. Because systolic blood pressure has direct influence on carotid distensibility, we also adjusted carotid distensibility values for the mean systolic blood pressure in all of the groups using 2-way ANCOVA analysis.
24-Hour Blood Pressure Monitoring
To exclude masked HTN (ie, normal office with elevated ambulatory blood pressure monitoring), we performed 24-hour blood pressure monitoring with a SpaceLabs device (model 90207, SpaceLabs Medical, Inc) in the control and OSA groups. Blood pressure was measured every 10 minutes during the day (8 AM to 11 PM) and every 20 minutes during the night (11 PM to 8 AM) with an appropriate cuff placed on a nondominant arm. Participants were instructed to perform their ordinary daily activities and not to move their arm during the ongoing measurement. Normal values were considered when systolic and diastolic blood pressures were <135 and 85 mm Hg for daytime and <120 and 70 mm Hg for nighttime, respectively.23
Blood Samples
Venous blood was collected from all of the participants for the measurement of glucose, total cholesterol, low-density lipoprotein, high-density lipoprotein, and red blood cell count.
Statistical Analysis
Data were analyzed with SPSS 10.0 statistical software. Quantitative variables are expressed as means±SDs. Comparisons between groups were made by 2-way ANOVA, and Bonferroni posthoc group comparisons (
=0.05 level of significance) were used to determine differences across the 4 groups. Linear regression models with vascular parameters, including carotid IMT, carotid diameter, and carotid distensibility as dependent variables and independent variables including age, body mass index, systolic and diastolic blood pressures, cholesterol, AHI, and minimal oxygen saturation, were constructed. Multiple regression analysis was used to identify variables that were independently associated with the vascular parameters and to adjust for possible confounding factors. A value of P<0.05 was considered significant.
| Results |
|---|
|
|
|---|
1 exclusion criteria, such as diabetes mellitus, smoking, or previous treatment for OSA. Ninety-four subjects (mean age: 46±6 years) were included in the final analysis (Figure 1). The 4 groups studied were similar in respect to several of the well-known risk factors for cardiovascular diseases, including age, sex, body mass index, and cholesterol levels (Table). As expected, there were significant differences in sleep parameters and blood pressure values in OSA groups and HTN groups, respectively. In controls and OSA groups, systolic blood pressure and diastolic blood pressure during awake (systolic: 122.1±8.0 versus 122.5±6.8 mm Hg; diastolic: 77.8±6.5 versus 77.8±5.3 mm Hg) and sleep (systolic: 106.8±12.0 versus 110.1±9.4 mm Hg; diastolic: 65.1±5.3 versus 65.9±5.1 mm Hg) were similar, respectively. In HTN and OSA+HTN groups, the numbers of antihypertensive medications and the times from HTN diagnosis were similar (Table). In addition, the percentages of antihypertensive medications in HTN and OSA+HTN groups were similar, including diuretics (65% versus 56%), β-blockers (40% versus 37%), calcium channel blockers (25% versus 26%), angiotensin-converting enzyme inhibitors (40% versus 44%), and angiotensin II receptor antagonists (20% versus 22%), respectively.
|
|
IMT was 597±82 µm for controls, 713±117 µm for the OSA group, 713±182 µm for the HTN group, and 837±181 µm for the OSA+HTN group (P<0.0001; Figure 2). Carotid diameter was 6575±383 µm for controls, 7117±805 µm for the OSA group, 7191±818 µm for the HTN group, and 7927±821 µm for the OSA+HTN group (P<0.001; Figure 3). Compared with controls, IMT and carotid diameter had similar increases in the OSA and HTN groups (P<0.05); a further significant increase was observed in OSA+HTN subjects (P<0.01). In percentage values, compared with the control group, carotid IMT and carotid diameter increased by 19.4% and 8.2% in the OSA group, 19.5% and 9.4% in the HTN group, and 40.3% and 20.6% in the OSA+HTN group, respectively.
|
|
According to Figure 4, carotid distensibility was 16.5±5.3 kPa–1·10–3 for controls, 14.2±4.2 kPa–1·10–3 for the OSA group, 13.1±3.6 kPa–1·10–3 for the HTN group, and 10.4±3.8 kPa–1·10–3 for the OSA+HTN group (P<0.01). Compared with controls, carotid distensibility was significantly decreased in HTN (P<0.05) and OSA+HTN subjects (P<0.001). In this last group, carotid distensibility was significantly lower than that in the OSA group (P<0.05). After adjustments for systolic blood pressure (mean systolic blood pressure of the entire group: 129.9 mm Hg), carotid distensibility was significantly decreased in OSA+HTN compared with that in controls (11.7±0.8 versus 15.1±0.9 kPa–1·10–3; P=0.03). In our study, we did not detect carotid plaques in healthy controls. This vascular finding was verified in 2 normotensive patients with OSA (8%), in 1 hypertensive patient without OSA (5%), and in 4 patients with both conditions (15%).
|
In the multivariate analysis performed on the whole study sample, IMT was positively related to systolic blood pressure and AHI (P<0.05). The only variable independently associated with carotid diameter was AHI (P<0.05). Age (P<0.05) and systolic blood pressure (P<0.01) were independently related to carotid distensibility.
| Discussion |
|---|
|
|
|---|
Atherosclerosis is the leading cause of coronary heart disease, stroke, and peripheral vascular disease.24 Stroke and coronary disease are the leading causes of death around the world, including in developing countries.25,26 Although distinct artery-dependent patterns of atherosclerosis exist,27 subclinical carotid atherosclerosis is reported to have a good correlation with coronary and intracranial atherosclerosis.28,29 In addition, the detection of early markers of atherosclerosis is a predictor of future cardiovascular events.8,30 For instance, OSA is associated with increased risk of stroke and myocardial infarction.3–6,31 In parallel with these studies, evidence is growing that OSA is an independent risk factor for atherosclerosis.9–11,32 The mechanisms whereby OSA may contribute to atherosclerosis are multiple and include systemic inflammation, oxidative stress, vascular smooth cell activation, increased adhesion molecule expression, lymphocyte activation, increased lipid lowering in macrophages, lipid peroxidation, high-density lipoprotein dysfunction, and endothelial dysfunction.11 Recent evidence in rabbits suggests that snoring promotes energy transmission to the carotid artery that could also be involved in atherosclerosis progression.33 In addition, the association between OSA and atherosclerosis could be mediated by the presence of HTN, a condition that is also associated with proatherogenic factors, such as endothelial dysfunction and inflammation.34 Typical patients with OSA share several risk factors for cardiovascular disease, including obesity and HTN, well established causes of atherosclerosis.14,35 In the present study, we characterized not only the relative impact of OSA on validated markers of early atherosclerosis36–39 but also the impact of the concomitant HTN, a very common condition associated with OSA.12,13 We described previously that severe OSA and HTN are associated with arterial stiffness and heart structure abnormalities of similar magnitude, with additive effects when both conditions coexist.16 However, to the best of our knowledge, the effects of OSA and HTN in isolation and the impact of the association of OSA and HTN on carotid atherosclerosis were not described previously. In the present study, we found that, compared with controls, IMT and carotid diameter had a similar increase in OSA and HTN groups, and a further significant increase was observed in OSA+HTN subjects. Further indicating the relative role of OSA, AHI was independently associated with carotid IMT and diameter in the multivariate analysis.
Our results suggest that OSA and HTN presented a distinct pattern of vascular damage. As discussed, AHI was independently associated with carotid IMT and diameter but not with carotid distensibility. Systolic blood pressure was also independently related to carotid IMT. Only age and systolic blood pressure were related to carotid distensibility. Although OSA seems to be more involved with structural damage of this elastic artery, the presence of HTN could negatively influence both the structural and functional properties, because carotid distensibility reflected the functional properties of this vessel.40 However, when we performed blood pressure adjustments, we found that only patients with OSA+HTN had lower carotid distensibility than controls. Because there is evidence that carotid distensibility is a good predictor of coronary heart disease,41 our results suggest that the common association of OSA and HTN may particularly impact on cardiovascular disease, independent of blood pressure values.
Our study has some strengths and limitations. The strengths include the availability of polysomnography data, which is the gold standard for OSA diagnosis, and the careful selection of matched controls and hypertensive patients at low risk for OSA, further confirmed by polysomnography. We also excluded masked HTN in the control and OSA groups, a clinical situation that seems not to be uncommon in apparently normotensive patients with OSA.42 The limitation is the fact that the direct comparison of the effects of 2 distinct conditions (OSA and HTN) must be made with caution. All of the OSA patients had moderate-to-severe disease that was not being treated, whereas all of the HTN patients were receiving treatment (although their mean systolic blood pressure was not fully controlled, remaining in stage 1 HTN). However, it is well recognized that HTN patients receiving optimal treatment have higher IMT and are at increased risk for cardiovascular disease than are normotensive subjects.43 Therefore, our study design corresponds with what is commonly seen in clinical practice. Another important point is that patients with OSA and HTN had a significantly greater increase in IMT and carotid diameter than did patients with HTN, despite taking similar antihypertensive medications. This fact reinforces the relative role of OSA in atherosclerosis. Second, although finger blood pressure accurately estimates intra-arterial blood pressure,22 an estimation of carotid blood pressure is preferred. Third, we did not perform 24-hour blood pressure monitoring in the HTN and OSA+HTN groups. Patients with OSA+HTN may have a higher nighttime blood pressure than patients with OSA or HTN alone, and this fact could be involved in the vascular damage promoted by this common association. Finally, our study was not designed to evaluate more advanced atherosclerotic lesions, such as carotid plaques. Future studies should be performed to explore the additive effects of OSA and HTN on atherosclerotic plaques in comparison with each condition alone.
Perspectives
The clinical implication of the present study is the demonstration of additive effects on markers of atherosclerosis in patients with OSA and HTN. These findings could be implicated in the rate of progression of carotid atherosclerosis in these patients, which could further contribute to increase the risk of stroke. Considering that the underdiagnosis of OSA in patients with HTN is still common and that continuous positive airway pressure therapy in patients with OSA has beneficial effects on blood pressure44 and early markers of atherosclerosis10 and decreases fatal and nonfatal cardiovascular events (including stroke),3 our results reinforce the importance of OSA in patients with HTN.
| Acknowledgments |
|---|
The study was supported by FAPESP, CNPq, and Fundação Zerbini.
Disclosures
None.
Received July 10, 2008; first decision July 29, 2008; accepted October 23, 2008.
| References |
|---|
|
|
|---|
2. Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier Nieto F, O'Connor GT, Boland LL, Schwartz JE, Samet JM. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med. 2001; 163: 19–25.
3. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005; 365: 1046–1053.[Medline] [Order article via Infotrieve]
4. Arzt M, Young T, Finn L, Skatrud JB, Bradley TD. Association of sleep-disordered breathing and the occurrence of stroke. Am J Respir Crit Care Med. 2005; 172: 1447–1451.
5. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005; 353: 2034–2041.
6. Munoz R, Duran-Cantolla J, Martínez-Vila E, Gallego J, Rubio R, Aizpuru F, De La Torre G. Severe sleep apnea and risk of ischemic stroke in the elderly. Stroke. 2006; 37: 2317–2321.
7. Valham F, Mooe T, Rabben T, Stenlund H, Wiklund U, Franklin KA. Increased risk of stroke in patients with coronary artery disease and sleep apnea: a 10-year follow-up. Circulation. 2008; 118: 955–960.
8. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007; 115: 459–467.
9. Drager LF, Bortolotto LA, Lorenzi MC, Figueiredo AC, Krieger EM, Lorenzi-Filho G. Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med. 2005; 172: 613–618.
10. Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi-Filho G. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med. 2007; 176: 706–712.
11. Lorenzi-Filho G, Drager LF. Obstructive sleep apnea and atherosclerosis: a new paradigm. Am J Respir Crit Care Med. 2007; 175: 1219–1221.
12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206–1252.
13. Drager LF, Pereira AC, Barreto-Filho JA, Figueiredo AC, Krieger JE, Krieger EM, Lorenzi-Filho G. Phenotypic characteristics associated with hypertension in patients with obstructive sleep apnea. J Hum Hypertens. 2006; 20: 523–528.[CrossRef][Medline] [Order article via Infotrieve]
14. Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation. 2004; 109: III15–III19.[Medline] [Order article via Infotrieve]
15. Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med. 1999; 131: 485–491.
16. Drager LF, Bortolotto LA, Figueiredo AC, Silva BC, Krieger EM, Lorenzi-Filho G. Obstructive sleep apnea, hypertension and their interaction on arterial stiffness and heart remodeling. Chest. 2007; 131: 1379–1386.[CrossRef][Medline] [Order article via Infotrieve]
17. Bortolotto LA, Blacher J, Kondo T, Takazawa K, Safar ME. Assessment of vascular aging and atherosclerosis in hypertensive subjects: second derivative of photoplethysmogram versus pulse wave velocity. Am J Hypertens. 2000; 13: 165–171.[CrossRef][Medline] [Order article via Infotrieve]
18. Bortolotto LA, Safar ME, Billaud E, Lacroix C, Asmar R, London GM, Blacher J. Plasma homocysteine, aortic stiffness, and renal function in hypertensive patients. Hypertension. 1999; 34: 837–842.
19. Laurent S, Caviezel B, Beck L, Girerd X, Billaud E, Boutouyrie P, Hoeks A, Safar M. Carotid artery distensibility and distending pressure in hypertensive humans. Hypertension. 1994; 23: 878–883.
20. Bortolotto LA, Hanon O, Franconi G, Boutouyrie P, Legrain S, Girerd X. The aging process modifies the distensibility of elastic but not muscular arteries. Hypertension. 1999; 34: 889–892.
21. Hanon O, Luong V, Mourad JJ, Bortolotto LA, Jeunemaitre X, Girerd X. Aging, carotid artery distensibility, and the Ser422Gly elastin gene polymorphism in humans. Hypertension. 2001; 38: 1185–1189.
22. Imholz BP, Langewouters GJ, van Montfrans GA, Parati G, van Goudoever J, Wesseling KH, Wieling W, Mancia G. Feasibility of ambulatory, continuous 24-hour finger arterial pressure recording. Hypertension. 1993; 21: 65–73.
23. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ; Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005; 45: 142–161.
24. Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, Thompson RW, Topper JN, Annex BH, Rundback JH, Fabunmi RP, Robertson RM, Loscalzo J; American Heart Association. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation. 2004; 109: 2617–2625.
25. Mansur AP, Favarato D, Souza MF, Avakian SD, Aldrighi JM, César LA, Ramires JA. Trends in death from circulatory diseases in Brazil between 1979 and 1996 [published correction appears in Arq Bras Cardiol. 2001;77:204][in Portuguese]. Arq Bras Cardiol. 2001; 76: 497–510.[Medline] [Order article via Infotrieve]
26. Pontes-Neto OM, Silva GS, Feitosa MR, de Figueiredo NL, Fiorot JA Jr, Rocha TN, Massaro AR, Leite JP. Stroke awareness in Brazil: alarming results in a community-based study. Stroke. 2008; 39: 292–296.
27. Dalager S, Paaske WP, Kristensen IB, Laurberg JM, Falk E. Artery-related differences in atherosclerosis expression: implications for atherogenesis and dynamics in intima-media thickness. Stroke. 2007; 38: 2698–2705.
28. Young W, Gofman JW, Tandy R, Malamud N, Waters ESG. The quantitation of atherosclerosis: III. The extent of correlation of degrees of atherosclerosis within and between the coronary and cerebral vascular beds. Am J Cardiol. 1960; 6: 300–308.[CrossRef]
29. Mathur KS, Patney NL, Kumar V. Atherosclerosis in India: an autopsy study of the aorta and the coronary, cerebral, renal, and pulmonary arteries. Circulation. 1961; 24: 68–75.
30. Lorenz MW, von Kegler S, Steinmetz H, Markus HS, Sitzer M. Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke. 2006; 37: 87–92.
31. Bassetti CL, Milanova M, Gugger M. Sleep-disordered breathing and acute ischemic stroke: diagnosis, risk factors, treatment, evolution, and long-term clinical outcome. Stroke. 2006; 37: 967–972.
32. Savransky V, Nanayakkara A, Li J, Bevans S, Smith PL, Rodriguez A, Polotsky VY. Chronic intermittent hypoxia induces atherosclerosis. Am J Respir Crit Care Med. 2007; 175: 1290–1297.
33. Amatoury J, Howitt L, Wheatley JR, Avolio AP, Amis TC. Snoring-related energy transmission to the carotid artery in rabbits. J Appl Physiol. 2006; 100: 1547–1553.
34. Watson T, Goon PK, Lip GY. Endothelial progenitor cells, endothelial dysfunction, inflammation, and oxidative stress in hypertension. Antioxid Redox Signal. 2008; 10: 1079–1088.[Medline] [Order article via Infotrieve]
35. Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. J Am Coll Cardiol. 2008; 51: 944–955.
36. Simon A, Gariepy J, Chironi G, Megnien JL, Levenson J. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens. 2002; 20: 159–169.[CrossRef][Medline] [Order article via Infotrieve]
37. de Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart JC, Kastelein JJ. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation. 2004; 109: III33–III38.[Medline] [Order article via Infotrieve]
38. Giannattasio C, Capra A, Facchetti R, Viscardi L, Bianchi F, Failla M, Colombo V, Grieco A, Mancia G. Relationship between arterial distensibility and coronary atherosclerosis in angina patients. J Hypertens. 2007; 25: 593–598.[Medline] [Order article via Infotrieve]
39. Lane HA, Smith JC, Davies JS. Noninvasive assessment of preclinical atherosclerosis. Vasc Health Risk Manag. 2006; 2: 19–30.[CrossRef][Medline] [Order article via Infotrieve]
40. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, Target R, Levy BI. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension. 1995; 26: 485–490.
41. Leone N, Ducimetière P, Gariépy J, Courbon D, Tzourio C, Dartigues JF, Ritchie K, Alpérovitch A, Amouyel P, Safar ME, Zureik M. Distension of the carotid artery and risk of coronary events: the three-city study. Arterioscler Thromb Vasc Biol. 2008; 28: 1392–1397.
42. Baguet JP, Lévy P, Barone-Rochette G, Tamisier R, Pierre H, Peeters M, Mallion JM, Pépin JL. Masked hypertension in obstructive sleep apnea syndrome. J Hypertens. 2008; 26: 885–892.[Medline] [Order article via Infotrieve]
43. de Simone G, Roman MJ, Koren MJ, Mensah GA, Ganau A, Devereux RB. Stroke volume/pulse pressure ratio and cardiovascular risk in arterial hypertension. Hypertension. 1999; 33: 800–805.
44. Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension. 2007; 50: 417–423.
Related Article:
Hypertension 2009 53: 1-3.
This article has been cited by other articles:
![]() |
J. S. Floras Hypertension, Sleep Apnea, and Atherosclerosis Hypertension, January 1, 2009; 53(1): 1 - 3. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |